Thus the inhibition of the intestinal DGAT1 may be sufficient to improve metabolic disorders, suggesting that the intestine-targeted DGAT1 inhibitor shows beneficial metabolic effects without skin aberrations. Here, DGAT1 is linked to Other metabolic disease.